新闻资讯

新闻资讯

NEWS
Check category
>
>
>
The pharmaceutical industry should be fully localized

The pharmaceutical industry should be fully localized

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-04-02 10:44
  • Views:

The pharmaceutical industry should be fully localized

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2020-04-02 10:44
  • Views:
Information

The medical and health industry not only undertakes the task of creating a healthy nation, it can also become a profit-creating "golden industry"

 

pic

 

Enterprises under the "Hands of Medical Insurance"

It is an established fact that drug prices in 2020 will fall sharply under the control of the "hands of medical insurance". The resolute implementation of policies such as mass purchase, two-invoice system, and medical insurance negotiations has changed the way companies have survived in the past. Consistency evaluation + normalization of procurement methods with volume procurement is just the basic threshold for participating in the market and will not become a competitive advantage of the enterprise.
Under this circumstance, if companies want to stand out, innovative drugs will be the subject of a long period of time in the future, but waiting and watching the medical insurance negotiations for innovative drugs means that there will be no price cuts if they are not innovative drugs. It is certainly not enough for companies to have innovative drugs. They also need to have continuous innovation capabilities and stepped pipeline products in order to better go on. In addition, in order to better participate in the market, product cost management is the top priority.

The era of "national replacement" is coming

At the beginning of April, CDE publicly solicited several guidelines for clinical trials of biosimilars, which showed that the era of drug substitution is truly coming. Imported medicines are expensive, and domestic medicines can greatly reduce the burden on patients, especially for the high-cost treatment of tumors or autoimmune diseases. It is urgent to reduce the cost of treatment for patients.
Some predictions point out that 2019 is the first year of the explosive launch of biosimilars in my country in 5 years. It is expected that starting from 2019, 5-10 biosimilars will be approved for marketing every 5 years. In the chemical drug market, the implementation of the consistency evaluation work in 2016 has improved the overall level of my country's pharmaceutical industry.

Localization of the pharmaceutical industry

In the era of "national replacement", the pharmaceutical industry should realize localization. China is a huge market for the pharmaceutical industry, but at present, most of my country's pharmaceutical market has been occupied by large foreign companies. In the face of this huge cake, foreign manufacturers are digging for gold, while domestic manufacturers are still struggling.
Under the trend of drug localization, in order to better participate in the market, pharmaceutical companies must pay attention to the competitiveness of their own products, including the cost. Looking ahead, the materials used by pharmaceutical companies in the drug R&D and production process are still keen on imported products with higher prices than domestic brands. This may have something to do with the common thinking of the Chinese that the quality of domestic products is worse than that of imported products. But friends, we are fortunate to be at a stage where we are experiencing the rising and then rising capabilities of all aspects of the country. At this time when the overall national strength is far ahead, domestic brands are not inferior to imports, or even better.
As Professor Li Ling from the China Center for Economic Research of Peking University said: "The pharmaceutical industry should be fully localized. The medical and health industry not only undertakes the task of creating a healthy nation, it can also become a profit-creating "golden industry." The localization of the pharmaceutical industry There is no precedent in the world. India’s experience in this area can give China some enlightenment. China’s pharmaceutical industry should follow India’s example and implement full localization."

 

Every medical person is a witness, pioneer and builder of the new era of medicine.

推荐新闻

Service Hotline

0755-84564291

0755-23250337

Email: betty_huang@jeanstandard.com
Address: Room 910, Building 2 of AIPARK, Anbo Innovation Industrial Park, No.2 Baolong Fourth Road, Baolong Street, Longgang District, Shenzhen 

友情链接 / LINKS            华兰生物      正大天晴药业      百奥泰      齐鲁制药      绿叶制药      上海医药      恒瑞      复星医药      三生国健      特瑞思

热门关键词                     层析介质      细胞培养      生产设备      临床药品      二次包装

CopyRight © 2021 Shenzhen Jean Standard Biological Technology Co. Ltd